

#9 1645
RECEIVED
JUL 26 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Keith D. ALLEN

Serial No.: 09/903,377

Filed: July 10, 2001

For: Transgenic Mice Containing
Chemokine Receptor 9A Gene
Disruptions

Docket No.: R-365

Group Art Unit: 1645

Examiner: Unassigned

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 19, 2002 regarding the above-captioned application, Applicants submit herewith:

1. A Preliminary Amendment under 37 C.F.R. §1.115 with an amendment to Figure 2A of the above-referenced application;
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 19, 2002.


The Sequence Listing submitted on October 25, 2001, in computer readable format (CRF) and paper, contains all sequences disclosed in the application. Therefore, Applicants believe that a substitute Sequence Listing in CRF is not required. Moreover, the content of the paper and computer readable copies of the Sequence Listing submitted on December 5, 2001 are identical. The sequence listing submitted in this application merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, thus no new matter has been introduced into the application.

Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the sequence listing into the application.

Date: July 16, 2002

Respectfully submitted,

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
Tel. (650) 569-5100
Fax (650) 569-5280


Jane K. Babin, Reg. No. 47,224